Clinical Trial Detail

NCT ID NCT02987543
Title Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

prostate cancer

Therapies

Olaparib

Enzalutamide

Abiraterone

Age Groups: adult senior

Additional content available in CKB BOOST